Breast Cancer
RALT gene loss impedes the efficacy of HER-2 inhibitor
Published in Women's Health Weekly, August 25th, 2005
According to recent research published in the journal Oncogene, "an emerging paradigm holds that loss of negative signaling to receptor tyrosine kinases (RTKs) is permissive for their oncogenic activity. Herein, we have addressed tumor suppression by RALT/MIG-6, a transcriptionally controlled feedback inhibitor of ErbB RTKs, in breast cancer cells."
"Knockdown of RALT expression by RNAi enhanced the EGF-dependent proliferation of normal breast epithelial cells, indicating that loss of RALT signaling in breast epithelium may represent an advantageous condition during ErbB-driven...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Docetaxel
Alternative docetaxel administration schedule evaluated - Estrogen
Estrogen elicits cortical zone-specific effects on fetal adrenal gland growth - Obstetrics
Study reveals effective way for women to breathe easier during labor - Osteoporosis
Bone mineral density test helps determine osteoporosis treatment strategy - Sexual & Reproductive Health
Survey reveals personal sacrifices take a toll on infertile women - Aging
Premature ovarian aging studied, role of Gpr3 clarified - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
